TIDMOCTP
Oxford Cannabinoid Tech.Holdings
26 October 2021
26 October 2021
Oxford Cannabinoid Technologies Holdings plc
Appointment of North American Investor Relations Adviser
Oxford Cannabinoid Technologies Holdings plc ("OCTP" or "the
Company"), the holding company of Oxford Cannabinoid Technologies
Ltd ("OCT"), a pharmaceutical company developing prescription
cannabinoid medicines for approval by key medicines regulatory
agencies worldwide and targeting the US$ multi-billion pain market,
is pleased to announce the appointment of Harbor Access LLC
("Harbor Access"), a US strategic investor relations adviser, based
in Stamford, Connecticut.
Harbor Access will provide North American investor awareness
support to OCTP, particularly in relation to the forthcoming
admission to trading of the Company's shares on the OTC QB Market
("OTC QB", the mid-tier OTC Equity Market in the United States),
under the ticker symbol "OCTHF".
Admission is expected to take place in November and is an
important strategic step for the Company. It gives OTCP greater
exposure to a much wider audience of potential investors by easing
cross-border trading for the Company's US investors in addition to
its London Stock Exchange Main Market Listing.
There is no capital-raise being conducted in conjunction with
the application to trading on the OCT QB. OCTP's shares will
continue to be traded on the London Stock Exchange under the ticker
symbol "OCTP". Further information can be found at
www.otcmarkets.com/learn/market-101.
Commenting on the appointment, OCTP's Chief Operating Officer,
Clarissa Sowemimo-Coker, said: "As we move towards finalising our
US share trading facility on the OTC QB Market, local investor
knowledge and support are key to optimising our designation. Harbor
Access has worked with numerous dual-quoted companies, and we look
forward to having their support."
Jonathan Paterson, Managing Partner of Harbor Access, added: "We
are excited to work with the team at OCTP. The Company's ongoing
development of drug candidates for novel solutions for chronic pain
management will offer an exciting new investment opportunity for
the North American investment community."
As OCTP complete their OTC QB application process, Harbor Access
has been retained for an initial six-month contract to support
management with their application process and North American based
investor relations.
The Directors of the Company accept responsibility for the
content of this announcement.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained in this
announcement is of a non-regulatory nature.
Enquiries:
Oxford Cannabinoid Technologies +44 (0)20 3034 2820
Holdings plc
Dr John Lucas (CEO) john@oxcantech.com
Clarissa Sowemimo-Coker (COO) clarissa@oxcantech.com
Walbrook PR Limited
Paul Vann +44 (0)20 7933 8780
Nick Rome +44 (0)7768 807631
Nicholas Johnson oxcantech@walbrookpr.com
Harbor Access LLC
Richard Leighton Richard.Leighton@HarborAccessllc.com
Jonathan Paterson +1 (475) 455 9403
About Oxford Cannabinoid Technologies Holdings plc :
Oxford Cannabinoid Technologies Holdings plc ("OCTP" or the
"Company") is the holding company of Oxford Cannabinoid
Technologies Ltd ("OCT") (together the "Group"), a pharmaceutical
company developing prescription cannabinoid medicines for approval
by key medicines regulatory agencies worldwide and targeting the U$
multi-billion pain market. Cannabinoids are compounds found in the
cannabis plant that have been shown to have a range of therapeutic
effects on the body, including pain relief. The Group has a clearly
defined path to commercialisation, revenues and growth. The Group
is developing drug candidates through clinical trials to gain
regulatory approval (FDA/MHRA/EMA) that will enable medical
professionals to prescribe them with confidence.
The Group's portfolio aims to balance risk, value and time to
market, whilst ensuring market exclusivity around all its key
activities. The Group's lead compound, OCT461201, is a highly
potent and selective CB2 agonist and is being developed by OCT in a
solid oral dosage form. OCT is conducting pre-clinical testing and
development with pre-clinical trials scheduled for 2022. The
Group's product pipeline also uses a balanced drug product strategy
that employs both natural and synthetic compounds for the treatment
of rare diseases and includes chemically modified phytocannabinoids
with improved drug-like characteristics and a proprietary library
of cannabinoids.
OCTP operates a partnership model with external academic and
commercial partners, including the University of Oxford with whom
OCT has had an umbrella research collaboration since 13 March
2018.
Caution regarding forward looking statements
Certain statements in this announcement, are, or may be deemed
to be, forward looking statements. Forward looking statements are
identi ed by their use of terms and phrases such as "believe",
"could", "should" "envisage", "estimate", "intend", "may", "plan",
"potentially", "expect", "will" or the negative of those,
variations or comparable expressions, including references to
assumptions. These forward-looking statements are not based on
historical facts but rather on the Directors' current expectations
and assumptions regarding the Company's future growth, results of
operations, performance, future capital and other expenditures
(including the amount, nature and sources of funding thereof),
competitive advantages, business prospects and opportunities. Such
forward looking statements re ect the Directors' current beliefs
and assumptions and are based on information currently available to
the Directors.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAPPGWWUUPGUWQ
(END) Dow Jones Newswires
October 26, 2021 02:00 ET (06:00 GMT)
Oxford Cannabinoid Techn... (LSE:OCTP)
Historical Stock Chart
From Aug 2024 to Sep 2024
Oxford Cannabinoid Techn... (LSE:OCTP)
Historical Stock Chart
From Sep 2023 to Sep 2024